PCSA Stock Overview
Processa Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Processa Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.43 |
52 Week High | US$18.00 |
52 Week Low | US$1.40 |
Beta | 0.52 |
1 Month Change | 11.98% |
3 Month Change | -33.79% |
1 Year Change | -77.93% |
3 Year Change | -98.55% |
5 Year Change | -99.28% |
Change since IPO | -99.94% |
Recent News & Updates
Recent updates
We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully
Dec 12Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?
Oct 20Processa Pharmaceuticals GAAP EPS of $0.53 beats by $0.73
Aug 12We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully
Jul 07We're Not Very Worried About Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Rate
Jan 20Processa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans
Aug 26Processa Pharmaceuticals (PCSA) Presents At LD Micro Invitations XI Virtual Conference - Slideshow
Jun 15What Percentage Of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Do Insiders Own?
Mar 15Processa Pharmaceuticals: Multiple Shots On Goal With Total TAM Of $8B - Worth A Look
Jan 29How Many Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Did Insiders Buy, In The Last Year?
Jan 20Shareholder Returns
PCSA | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 55.8% | -0.6% | 1.0% |
1Y | -77.9% | 10.6% | 21.9% |
Return vs Industry: PCSA underperformed the US Pharmaceuticals industry which returned 13.2% over the past year.
Return vs Market: PCSA underperformed the US Market which returned 24.9% over the past year.
Price Volatility
PCSA volatility | |
---|---|
PCSA Average Weekly Movement | 23.5% |
Pharmaceuticals Industry Average Movement | 9.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PCSA's share price has been volatile over the past 3 months.
Volatility Over Time: PCSA's weekly volatility has decreased from 32% to 23% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2011 | 13 | George Ng | www.processapharmaceuticals.com |
Processa Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. Its pipeline includes three Chemotherapy drugs, including Capecitabine, PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; Gemcitabine, PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers; and Irinotecan, PCS11T to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.
Processa Pharmaceuticals, Inc. Fundamentals Summary
PCSA fundamental statistics | |
---|---|
Market cap | US$6.94m |
Earnings (TTM) | -US$11.12m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs PCSA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PCSA income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$11.12m |
Earnings | -US$11.12m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -3.89 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did PCSA perform over the long term?
See historical performance and comparison